| Literature DB >> 28962384 |
Carlos Alberto F Ramos1, Rita de Cássia da S Sá1, Mateus F Alves1, Rubens B Benedito1, Damião P de Sousa2, Margareth de Fátima F M Diniz1,2, Maria Salete T Araújo3, Reinaldo N de Almeida1,4.
Abstract
The aim of the present work was to develop a biochemical, histologic and immunohistochemical study about the potential hepatotoxic effect of d-limonene - a component of volatile oils extracted from citrus plants. Blood alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) from d-limonene-treated animals were determined and compared to morphologic hepatic lesions in order to investigate the possible physiopathologic mechanisms involved in the liver toxicity, in experimental animals treated with d-limonene. Wistar rats were randomly divided into seven groups: two control groups (untreated or receiving only vehicle, tween-80); one positive control (vehicle); two experimental groups treated with d-limonene at doses of 25 mg/kg/day and 75 mg/kg/day for 45 days, and two other groups treated with the same doses for 30 days and kept under observation during 30 more days. Biochemical data showed significant reduction in ALT levels in the animals treated with 75 mg/kg of d-limonene. Histological analysis revealed some hepatocyte morphological lesions, including hydropic degeneration, microvesicular steatosis and necrosis, Kupffer cell hyperplasia and incipient fibrosis. By immunohistochemistry, influx of T (CD3+) and cytotoxic (CD8+) lymphocytes was observed in the rats treated with d-limonene at both dose levels. In conclusion, it is possible that d-limonene has been directly responsible for hepatic parenchymal and matrix damage following subchronic treatment with d-limonene.Entities:
Keywords: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Essential oils; HE, hematoxylin–eosin; Hepatotoxicity; Histopathology; Limonene; Rodent
Year: 2015 PMID: 28962384 PMCID: PMC5598502 DOI: 10.1016/j.toxrep.2015.01.001
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Animal groups and treatments.
| Group | Drug | Duration of treatment (days) | |
|---|---|---|---|
| I | – | 8 | – |
| II | Tween-80 | 10 | 45 |
| III | 20% ethanol | 10 | 45 |
| IV | 25 mg/kg of | 10 | 45 |
| V | 75 mg/kg of | 10 | 45 |
| VI | 25 mg/kg of | 5 | 30 |
| VII | 75 mg/kg of | 5 | 30 |
Criteria for histological evaluation of the degree of fibrosis (A), degree of portal lymphocyte infiltration (B), degree of periportal and periseptal lymphocyte infiltration (C) and degree of necroinflammatory activity in the hepatic tissue (D).
| A | B | ||
|---|---|---|---|
| Score | Lobular architecture | Degree | Septal and portal inflammatory infiltrate |
| F0 | Normal (absence of fibrosis) | 0 | Absent of rare portal lymphocytes |
| F1 | Fibrous extension of portal spaces | 1 | Discreet increase in the number of portal lymphocytes |
| F2 | Fibrous extension of portal spaces with portal-portal septa | 2 | Moderate increase in the number of portal lymphocytes |
| F3 | Fibrous extension of portal spaces with portal-portal and portal-central septa, with possible nodule formation | 3 | Marked increase in the number of portal lymphocytes |
| F4 | Cirrhosis with predominant nodular areas in relation to the remaining lobules | 4 | Strongly marked increase in the number of portal lymphocytes |
AST, ALT and ALP serum levels in control, ethanol and d-limonene-treated rats after 45 days of treatment.
| Enzyme (UI/L) | Group | |||
|---|---|---|---|---|
| II | III | IV | V | |
| AST | 168.6 ± 15.8 | 171.2 ± 8.7 | 150.2 ± 10.4 | 147.2 ± 11.4 |
| ALT | 66.7 ± 4.5 | 65.1 ± 3.7 | 63.2 ± 3.7 | 50.8 ± 3.0 |
| ALP | 153.1 ± 20.7 | 123.1 ± 5.4 | 118.7 ± 8.5 | 104.5 ± 11.5 |
Data expressed by mean ± standard error (S.E.M).
P < 0.05, Tukey's test II – control (tween-80), III – 20% ethanol, IV – 25 mg/kg, and V – 75 mg/kg.
Fig. 1Liver of control and d-limonene treated rats.
Degree of portal inflammation and parenchymal (lobular) of control, ethanol and d-limonene-treated rats during 30 days and 45 days.
| Group | Degree of portal hepatic inflammation | Degree of portal hepatic inflammation | Treatment (days) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 or 4 | 0 | 1 | 2 | 3 or 4 | ||
| I | 2 (25%) | 6 (75%) | 0 | 0 | 5 (62.5%) | 3 (37.5%) | 0 | 0 | - |
| II | 3 (30%) | 7 (70%) | 0 | 0 | 6 (60%) | 4 (40%) | 0 | 0 | 45 |
| III | 0 | 6 (60%) | 4 (40%) | 0 | 4 (40%) | 2 (20%) | 4 (40%) | 0 | 45 |
| IV | 0 | 5 (50%) | 5 (50%) | 0 | 1 (10%) | 3 (30%) | 6 (60%) | 0 | 45 |
| V | 2 (20%) | 7 (70%) | 1 (10%) | 0 | 0 | 5 (50%) | 5 (50%) | 0 | 45 |
| VI | 0 | 3 (60%) | 2 (40%) | 0 | 1 (20%) | 4 (80%) | 0 | 0 | 30 |
| VII | 1 (20%) | 4 (80%) | 0 | 0 | 0 | 3 (60%) | 2 (40%) | 0 | 30 |
I – control (without treatment), II – tween-80, III – 20% ethanol, IV – 25 mg/kg, V – 75 mg/kg, VI – 25 mg/kg, VII – 75 mg/kg.
Fig. 2Degree of hepatic portal inflammation (a) and parenchymal inflammation (b).
Fig. 3Histological section.